Pfizer stops commercialization of hemophilia gene therapy Beqvez Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors.

Feb25: #Pfizer stops commercialization of #hemophilia #gene therapy #Beqvezhigh, priced at $3.5 million.
We need a reflection on therapies #priced millions of dollars for a one-course
@belentarrafeta.bsky.social @elstorreele.bsky.social @elizabethpisani.ternyata.org
www.reuters.com/business/hea...